Clinical trial
A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Antiviral Efficacy of PPI-668 in Healthy Volunteers and Patients With HCV Genotype-1 Infection
NCT01448200 is registered in ClinicalTrials.gov with Presidio Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Antiviral Efficacy of PPI-668 in Healthy Volunteers and Patients With HCV Genotype-1 Infection
- Lead sponsor
- Presidio Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2011
- Completion date
- November 30, 2012
- Enrollment
- 82 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.